Literature DB >> 21284703

Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours.

Milena Gusella1, Felice Pasini, Caterina Bolzonella, Silvia Meneghetti, Carmen Barile, Antonio Bononi, Silvia Toso, Daniela Menon, Giorgio Crepaldi, Yasmina Modena, Laura Stievano, Roberto Padrini.   

Abstract

AIM: Gemcitabine (GEM) enters normal and tumour cells via concentrative (CNT) and equilibrative nucleoside transporters (ENT) and is subsequently deaminated to the inactive difluorodeoxyurine (dFdU) by cytidine deaminase (CDA). The aim of our study was to ascertain whether the nucleoside transporter genotype and the CDA activity phenotype can predict total GEM plasma clearance.
METHODS: Forty-seven patients received GEM 1000-1250mgm(-2) i.v. over 30min. Plasma concentrations of GEM and dFdU were measured and individual pharmacokinetic profiles were determined. CDA activity was measured ex vivo in plasma samples. The two most common hENT1 and hCNT1 polymorphisms were determined from genomic DNA.
RESULTS: Multivariate analysis revealed that GEM plasma clearance (CL) was positively correlated with the end of infusion dFdU : GEM ratio (P < 0.0001), which is a marker of in vivo CDA activity. The ENT1 genotype characterized by high transport capacity (G/G) and age were inversely correlated with CL (P= 0.027 and 0.048, respectively). A strong correlation was found between end of infusion GEM concentration and area under the concentration-time curve from time 0 to infinity (AUC(0,∞)) (r(2) = 0.77).
CONCLUSIONS: Our results confirm the role of CDA and age on the interindividual variability of GEM CL and show the contribution of the hENT1 genotype for the first time.
© 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21284703      PMCID: PMC3045553          DOI: 10.1111/j.1365-2125.2010.03838.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  30 in total

1.  Differential expression of human nucleoside transporters in normal and tumor tissue.

Authors:  M Pennycooke; N Chaudary; I Shuralyova; Y Zhang; I R Coe
Journal:  Biochem Biophys Res Commun       Date:  2001-01-26       Impact factor: 3.575

2.  The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.

Authors:  Jennifer Spratlin; Randeep Sangha; Darryl Glubrecht; Laith Dabbagh; James D Young; Charles Dumontet; Carol Cass; Raymond Lai; John R Mackey
Journal:  Clin Cancer Res       Date:  2004-10-15       Impact factor: 12.531

3.  Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase.

Authors:  D Y Bouffard; J Laliberté; R L Momparler
Journal:  Biochem Pharmacol       Date:  1993-05-05       Impact factor: 5.858

Review 4.  Clinical pharmacology and pharmacogenetics of gemcitabine.

Authors:  Andrea Wong; Ross A Soo; Wei-Peng Yong; Federico Innocenti
Journal:  Drug Metab Rev       Date:  2009       Impact factor: 4.518

5.  Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populations.

Authors:  Jennifer H Gray; Lara M Mangravite; Ryan P Owen; Thomas J Urban; Wendy Chan; Elaine J Carlson; Conrad C Huang; Michiko Kawamoto; Susan J Johns; Douglas Stryke; Thomas E Ferrin; Kathleen M Giacomini
Journal:  Mol Pharmacol       Date:  2004-03       Impact factor: 4.436

6.  Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer.

Authors:  Hiroyuki Achiwa; Tetsuya Oguri; Shigeki Sato; Hiroyoshi Maeda; Takashi Niimi; Ryuzo Ueda
Journal:  Cancer Sci       Date:  2004-09       Impact factor: 6.716

Review 7.  Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy.

Authors:  Vijaya L Damaraju; Sambasivarao Damaraju; James D Young; Stephen A Baldwin; John Mackey; Michael B Sawyer; Carol E Cass
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

Review 8.  Nucleoside transporters in the disposition and targeting of nucleoside analogs in the kidney.

Authors:  Lara M Mangravite; Ilaria Badagnani; Kathleen M Giacomini
Journal:  Eur J Pharmacol       Date:  2003-10-31       Impact factor: 4.432

9.  Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study.

Authors:  R Grunewald; H Kantarjian; M Du; K Faucher; P Tarassoff; W Plunkett
Journal:  J Clin Oncol       Date:  1992-03       Impact factor: 44.544

10.  A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.

Authors:  J L Abbruzzese; R Grunewald; E A Weeks; D Gravel; T Adams; B Nowak; S Mineishi; P Tarassoff; W Satterlee; M N Raber
Journal:  J Clin Oncol       Date:  1991-03       Impact factor: 44.544

View more
  10 in total

Review 1.  Contribution of tumoral and host solute carriers to clinical drug response.

Authors:  Jason A Sprowl; Torben S Mikkelsen; Hugh Giovinazzo; Alex Sparreboom
Journal:  Drug Resist Updat       Date:  2012-03-28       Impact factor: 18.500

2.  Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infection.

Authors:  Runyan Jin; Michael J Fossler; John G McHutchison; Charles D Howell; Thomas C Dowling
Journal:  AAPS J       Date:  2012-05-26       Impact factor: 4.009

3.  Chemotherapy-induced toxicity is highly heritable in Drosophila melanogaster.

Authors:  Galina Kislukhin; Maura L Murphy; Mahtab Jafari; Anthony D Long
Journal:  Pharmacogenet Genomics       Date:  2012-04       Impact factor: 2.089

Review 4.  [Will molecular diagnostics become established in pancreatic pathology?].

Authors:  B Sipos; J Sperveslage
Journal:  Pathologe       Date:  2013-11       Impact factor: 1.011

5.  CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer.

Authors:  Lorraine Pelosof; Sashidhar R Yerram; Nita Ahuja; Andrew Delmas; Ludmila Danilova; James G Herman; Nilofer S Azad
Journal:  Int J Cancer       Date:  2013-08-24       Impact factor: 7.396

6.  Novel regulation of equlibrative nucleoside transporter 1 (ENT1) by receptor-stimulated Ca2+-dependent calmodulin binding.

Authors:  Alex Bicket; Pedram Mehrabi; Zlatina Naydenova; Victoria Wong; Logan Donaldson; Igor Stagljar; Imogen R Coe
Journal:  Am J Physiol Cell Physiol       Date:  2016-03-23       Impact factor: 4.249

7.  Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels.

Authors:  Naotake Funamizu; Curtis Ray Lacy; Kaori Fujita; Kenei Furukawa; Takeyuki Misawa; Katsuhiko Yanaga; Yoshinobu Manome
Journal:  PLoS One       Date:  2012-05-16       Impact factor: 3.240

8.  Resistance of leukemia cells to cytarabine chemotherapy is mediated by bone marrow stroma, involves cell-surface equilibrative nucleoside transporter-1 removal and correlates with patient outcome.

Authors:  Patricia Macanas-Pirard; Richard Broekhuizen; Alfonso González; Claudia Oyanadel; Daniel Ernst; Patricia García; Viviana P Montecinos; Felipe Court; Mauricio Ocqueteau; Pablo Ramirez; Bruno Nervi
Journal:  Oncotarget       Date:  2017-04-04

9.  Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine.

Authors:  Justine M Grixti; Steve O'Hagan; Philip J Day; Douglas B Kell
Journal:  Front Pharmacol       Date:  2017-03-27       Impact factor: 5.810

10.  A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype.

Authors:  Marina Baretti; Enusha Karunasena; Marianna Zahurak; Rosalind Walker; Yang Zhao; Thomas R Pisanic; Tza-Huei Wang; Tim F Greten; Austin G Duffy; Elske Gootjes; Gerrit Meijer; Henk M W Verheul; Nita Ahuja; James G Herman; Nilofer S Azad
Journal:  Clin Transl Sci       Date:  2021-04-03       Impact factor: 4.689

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.